(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 6.3% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.95%.
Bioventus's revenue in 2026 is $576,300,000.On average, 6 Wall Street analysts forecast BVS's revenue for 2026 to be $51,068,990,810, with the lowest BVS revenue forecast at $49,304,736,151, and the highest BVS revenue forecast at $53,267,626,351. On average, 6 Wall Street analysts forecast BVS's revenue for 2027 to be $54,458,832,385, with the lowest BVS revenue forecast at $52,363,779,977, and the highest BVS revenue forecast at $57,635,660,259.
In 2028, BVS is forecast to generate $57,816,095,394 in revenue, with the lowest revenue forecast at $55,958,281,776 and the highest revenue forecast at $60,184,306,549.